Lymphocyte surface molecules as immune activation biomarkers

Area of Science:

• Immunology
• Transplantation Medicine
• Biomarker Discovery

Background:

• Lifelong immunosuppression is essential post-solid organ transplantation for HLA mismatched recipients.
• Current pharmacokinetic monitoring provides surrogate markers, lacking individual patient response prediction.
• There is a critical need for biomarkers indicating immune activation to tailor immunosuppressive therapies.

Purpose of the Study:

• To review experimental and clinical studies on surface molecules as immune monitoring tools.
• To critically discuss analytical and diagnostic challenges hindering clinical application.
• To explore the potential of T cell activation markers for personalized immunosuppression.

Main Methods:

• Flow cytometry analysis of T cell surface molecules (e.g., CD25, CD71, CD28, CD69, CD154, sCD30).
• Assessment of immunosuppressive drug effects via indirect cell function assays.
• Monitoring of activated T cells and soluble proteins in whole blood using immunoassays.

Main Results:

• T cell surface molecules are upregulated or shed upon activation, indicating immune status.
• Various molecules show potential for monitoring T cell activation in transplant patients.
• Immunoassays can measure soluble proteins indicative of immune response.

Conclusions:

• Surface molecules represent a promising avenue for individualizing immunosuppressive therapy.
• Analytical and diagnostic limitations currently impede the widespread clinical use of these biomarkers.
• Further research is needed to overcome obstacles for routine monitoring in transplant recipients.